San Francisco, California, April 23, 2018: A recent report by TMR Research, titled, “Smart Inhalers Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017 – 2025,” forecasts the market to bode well mainly due to a rising number of respiratory diseases.
Smart inhalers are becoming the most preferred way of treating and controlling respiratory diseases, mainly owing to their characteristics such as high efficiency, substantial potency against various ailments, and long-lasting than the traditional inhalers. Increasing pollution levels all over the globe are drastically increasing the occurrence of chronic obstructive pulmonary disorders, asthma, bronchitis, and others, which demands use of treatment options such as inhalers. A burgeoning healthcare industry, especially in context of respiratory disease treatments has also stoked the global smart inhalers market to depict a splendid growth.
Get Sample Copy of this Report @
However, high cost of smart inhaler devices poses as a hindrance to the market, especially in underdeveloped and developing regions where per capita income is less compared to the developed regions. Nonetheless, many manufacturers are focusing on producing less expensive smart inhaler devices, along with broadening their reach geographically. This is expected to neutralize the restraints up to a certain extent.
The global smart inhaler market depicts a highly competitive vendor landscape, albeit in its nascent stage. This is mainly due to a less regional reach of the inhalers, consequently translating in a less awareness among the masses. Vectura Group plc, Novartis AG, Propeller Health, Cohero Health, LLC, AstraZeneca plc, Propeller Health, Adherium Limited, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, OPKO Health, Inc., and Teva Pharmaceutical Industries Ltd., are key players operating in the global smart inhalers market.